Prostate cancer (CaP) and bladder urothelial cancer (BUC) are the two most common malignancies in urology, and both overexpress VPAC1. VPAC1 is overexpressed at the…
Read More
The cancer (tumor) profiling market is expected to grow at a CAGR of 19.1% over the next four years. This growth directly reflects the public’s…
Sushil K.Tripathia1 PardeepKumara Edouard J.Trabulsib SungKimaPeter A.McCuec CharlesIntenzoa AdamBergerd LeonardGomellabe Mathew L.Thakurae https://doi.org/10.1016/j.nucmedbio.2017.04.007Get rights and content Abstract Introduction Previously, our laboratory has shown that 64Cu-TP3805…
This publication has validated the Thomas Jefferson University hypothesis that prostate cancer can be detected non-invasively by a simple and reliable assay by targeting genomic VPAC…
Cancer diagnostics technology continues to evolve, with emerging science based in precision medicine beginning to dominate the industry. Even though global markets are primarily focused…
As cancer rates continue to rise, patients increasingly bear the brunt of both the financial and emotional costs related to their diagnosis. In an effort…
While genetic testing has been used for years to diagnose cancer, it is now finding new application in the identification of cancerous mutations that will…
